haloperidol sold brand name haldol among others typical antipsychotic haloperidol used treatment schizophrenia tics tourette syndrome mania bipolar disorder delirium agitation acute psychosis hallucinations alcohol may used mouth injection muscle haloperidol typically works within longacting formulation may used injection every four weeks people schizophrenia related illnesses either forget refuse take medication haloperidol may result movement disorder known tardive dyskinesia may neuroleptic malignant syndrome qt interval prolongation may occur latter particularly iv older people psychosis due dementia results increased risk taken pregnancy may result problems used people parkinsons haloperidol discovered paul prepared part structureactivity relationship investigation analogs pethidine world health organizations list essential commonly used typical commonly prescribed medication united states million haloperidol crystalline material melting temperature drug low solubility water ml soluble chloroform benzene methanol acetone also soluble hydrochloric acid mgml haloperidol used control symptoms haloperidol considered indispensable treating psychiatric emergency although newer atypical drugs gained greater role number situations outlined series consensus reviews published comparison antipsychotics schizophrenia haloperidol demonstrated standard effectiveness effective ziprasidone chlorpromazine asenapine approximately effective quetiapine aripiprazole less effective systematic review compared haloperidol placebo data animal experiments indicate haloperidol teratogenic embryotoxic high doses humans controlled studies exist reports pregnant women revealed possible damage fetus although women exposed multiple drugs pregnancy addition reports indicate neonates exposed antipsychotic drugs risk extrapyramidal andor withdrawal symptoms following delivery agitation hypertonia hypotonia tremor somnolence respiratory distress feeding disorder following accepted general principles haloperidol given pregnancy benefit mother clearly outweighs potential fetal haloperidol excreted breast milk studies examined impact haloperidol exposure breastfed infants cases adverse effects infant growth longterm treatment chronic psychiatric disorders daily dose reduced lowest level needed maintenance remission sometimes may indicated terminate haloperidol treatment graduallycitation needed addition longterm use routine monitoring including measurement bmi blood pressure fasting blood sugar lipids recommended due risk side forms therapy psychotherapy occupational therapyergotherapy social rehabilitation instituted properlycitation needed pet imaging studies suggested low doses preferable clinical response associated least occupancy receptors greater likely cause hyperprolactinaemia associated extrapyramidal side effects doses haloperidol greater mg increased risk side effects without improving patients responded doses even mg firstepisode maintenance treatment schizophrenia international consensus conference recommended reduction dosage every months minimal maintenance dose decanoate ester haloperidol haloperidol decanoate trade names haldol decanoate halomonth neoperidole much longer duration action often used people known noncompliant oral medication dose given intramuscular injection every two four iupac name haloperidol decanoate decanoate topical formulations haloperidol used treatment nausea research indicate therapy effective sources following lists adverse haloperidol highpotency typical antipsychotic tends produce significant extrapyramidal side effects according metaanalysis comparative efficacy tolerability antipsychotic drugs prone causing extrapyramidal side months use percent users gain haloperidol may common incidence unknown frequency rare incidence several lines evidence suggest haloperidol exhibits studies report association antipsychotic medications especially firstgeneration agents decline gray matter haloperidol may exert deleterious effects dorsolateral prefrontal cortex dlpfc attenuating bdnf transcription expression associated increase long noncoding rna bdnfas british national formulary recommends gradual withdrawal discontinuing antipsychotics avoid acute withdrawal syndrome rapid symptoms withdrawal commonly include nausea vomiting loss symptoms may include restlessness increased sweating trouble less commonly may feeling world spinning numbness muscle symptoms generally resolve short period tentative evidence discontinuation antipsychotics result may also result reoccurrence condition rarely tardive dyskinesia occur medication symptoms usually due side effects often encountered treatment mostly symptomatic involves intensive care stabilization vital functions early detected cases oral overdose induction emesis gastric lavage use activated charcoal tried case severe overdose antidotes bromocriptine ropinirole may used treat extrapyramidal effects caused haloperidol acting dopamine receptor agonistscitation needed ecg vital signs monitored especially qt prolongation severe arrhythmias treated antiarrhythmic overdose haloperidol general prognosis overdose good provided person survived initial phase haloperidol typical butyrophenonetype antipsychotic exhibits highaffinity dopamine receptor antagonism slow receptor dissociation effects similar drug binds preferentially receptors low dose mgkg respectively receptors higher dose mgkg given antagonism receptors beneficial positive symptoms schizophrenia antagonism receptors negative symptoms characteristic underlies haloperidols greater effect delusions hallucinations manifestations haloperidols negligible affinity histamine receptors muscarinic acetylcholine receptors yields antipsychotic lower incidence sedation weight gain orthostatic hypotension though higher rates treatment emergent extrapyramidal symptoms bioavailability oral haloperidol ranges however wide variance reported mean tmax different studies ranging hours hours drug well rapidly absorbed high bioavailability injected intramuscularly tmax minutes healthy individuals minutes patients schizophrenia mean decanoate injectable formulation intramuscular administration intended used intravenously plasma concentrations haloperidol decanoate reach peak six days injection falling thereafter approximate halflife three bioavailability intravenous iv injection rapid onset action seen within seconds hours apparent volume distribution duration action four six hours plasma levels five micrograms per liter typically seen therapeutic response ulrich et al clin pharmacokinet determination plasma levels rarely used calculate dose adjustments useful check compliance concentration haloperidol brain tissue higher compared blood levels slowly eliminated brain may explain slow disappearance side effects medication haloperidol heavily protein bound human plasma free fraction also extensively metabolized liver administered dose excreted unchanged urine greatest proportion hepatic clearance glucuronidation followed reduction cypmediated oxidation primarily haloperidol discovered paul developed belgian company janssen pharmaceutica submitted first clinical trials belgium later haloperidol approved us food drug administration fda april later marketed us countries brand name haldol mcneil haloperidol relatively inexpensive fold less expensive newer haloperidol inn ban usan aan approved name sold tradenames aloperidin bioperidolo brotopon dozic duraperidol germany einalon eukystol haldol common tradename us uk halol halosten keselan linton peluces serenace norodol turkey sigaperidolcitation needed haloperidol also used many different kinds animals nonselective tranquilization diminishing behavioral arousal veterinary settings including captivity httpsenwikipediaorgwikihaloperidol